微软及谷歌等加入针对以色列间谍软体公司NSO的法律诉讼
微软(MSFT.US)及谷歌在内的科技巨擘加入Facebook(FB.US)与以色列间谍软体公司NSO的法律诉讼,向联邦法院提交摘要文件,称NSO的工具功能强大兼且具有危险性。
NSO被指利用Facebook旗下WhatsApp的安全漏洞,对全球逾1,400人进行监视。NSO辩称,由於公司向警察及情报机构出售网络入侵工具,因此应享受豁免权免受外国政府起诉。加州地区法院於7月裁定NSO不能享有豁免权,其後NSO上诉至第九巡回法院。
微软、谷歌、思科(CSCO.US)、戴尔(DELL.US)旗下VMWare等为Facebook的诉讼向法院提交意见,认为授予NSO豁免权将让更多外国政府拥有强大而危险的网络监视工具。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.